Statement statement on need to strengthen prevention measures for healthcare-associated infections The following statement is to Kathy Warye, CEO of the Association for Professionals in Infection Control and Epidemiology : APIC relates with the increased rate of antibiotic-resistant infections. As high as 70 % according to recent reports New MRSA strains, as the pUSA03 – positive strain, provide evidence that the nature of these organisms is changing – producing infections that are increasingly resistant to our strongest antibiotics..
APIC advances its mission through education, research, collaboration, practice guidance, public policy and credentialing.
APIC also urges the consumer and health experts to the prudent use of antibiotics exercise with a dwindling arsenal of effective drugs and few new compounds on the horizon, healthcare facilities and consumers need misuse misuse and overuse of antibiotics. Controlling the growth of virulent multi-drug resistant organisms nationwide. The reduction of HAIs will require adequately resourced infection prevention departments within healthcare facilities the safety of patients the safety of patients, APIC stands ready to partner with health professionals, politicians and consumer groups to support and training in this important endeavor.Deliverability to complex lesions is further strengthened by the installation of a new, hard deliverable dilatation technologies. ‘It is extremely important for a series of options in selecting the correct treatment for patients hard coronary lesions,’Dean J. Kereiakes, Medical Director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati, Ohio , and a principal investigator for the TAXUS PERSEUS clinical trial evaluating the TAXUS Element A stent. ‘The Element Stent series is intended to by DES of DES solutions for interventional cardiologists by providing them the option treat patients with an paclitaxel, everolimus or bare-metal stent. After my experience, that TAXUS Element Stent being a high stock and compliant platform that has potential to simplifying complex procedures and lead to better results.
‘presents our platinum chromium Element Stent series a significant advancement in active substance – eluting stent innovation, ‘said David McFaul, Boston Scientific is Senior Vice President, International. ‘The revolutionary technology combination a new alloy for coronary stent a stent design stent design and develop a new system of. ‘.